A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628
← catalyst calendarSponsored by Praxis Precision Medicines (industry) · PRAX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
16actual
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-28 | actual | When the study began enrolling |
| Primary completion | 2025-06-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-05 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Intervention
- Drug: PRAX-628
Primary outcomes
what the primary-completion date above is the date OFTo assess the relative bioavailability of single 40 mg oral doses of PRAX-628 tablet as compared to PRAX-628 capsules
measured 28 days
To assess the relative bioavailability of single 40 mg oral doses of PRAX-628 tablet as compared to PRAX-628 capsules
measured 28 days
Permalink · PRAX's whole pipeline · Catalyst calendar · Every registered study · What changed